A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [6]
In the citing paper
“Application of the BCS in waiving BA/BE requirements is based on premises that if (1) two immediate-release (IR) drug formulations/products behave as oral solutions within the GI tract due to high solubility and rapid dissolution, (ii) no precipitation occurs in the GI tract once the API is dissolved, and (iii) the two IR formulations have the same in vivo dissolution profile under all intestinal”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
Citations
Cites
Diffusion, mass transfer in fluid systems
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0927 · Cited by 4,930
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
The effect of particle size distribution on dissolution rate and oral absorption
HINTZ, R., & JOHNSON, K. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90069-0 · Cited by 331
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Self-citationOh, D.-M., Curl, R. L., & Amidon, G. L. (1993) · Pharmaceutical Research · doi:10.1023/a:1018947113238 · Cited by 253
Self-citationRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Self-citationOberle, R. L., & Amidon, G. L. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061761 · Cited by 208
Self-citationRegional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202
Self-citationPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178
Self-citationIn Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants
Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., & Skelly, J. P. (1989) · Pharmaceutical Research · doi:10.1023/a:1015909716312 · Cited by 162
Self-citation
Research works printed but not linked: 5
- E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
- G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
- V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
- H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
- The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
Cited by
Items 401–500 of 1,018
Tannergren, C., Bergendal, A., Lennernäs, H., & Abrahamsson, B. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800261a · Cited by 141
Self-citationZakeri‐Milani, P., Barzegar-Jalali, M., Azimi, M., & Valizadeh, H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.04.015 · Cited by 145
“Class II drugs have a high absorption but a low dissolution rate; therefore, absorption is limited primarily by drug dissolution in the gastrointestinal tract [26].”
BackgroundResultInfluentialPopulation pharmacokinetic analysis of sorafenib in patients with solid tumours
Jain, L., Woo, S., Gardner, E. R., Dahut, W. L., Kohn, E. C., Kummar, S., Mould, D. R., Giaccone, G., Yarchoan, R., Venitz, J., et al. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03963.x · Cited by 145
Frank, K. J., Rosenblatt, K. M., Westedt, U., Hölig, P., Rosenberg, J., Mägerlein, M., Fricker, G., & Brandl, M. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.08.014 · Cited by 145
Gordon, S. (2015) · ALTEX · doi:10.14573/altex.1510051 · Cited by 144
“Optimizing permeability in contrast to receptor affinity according to “Lipinski’s rule of five” (Lipinski et al., 1997) has become a well-accepted new paradigm in drug discovery for medicinal chemists; such in vitro approaches are also widely used in pharma for the approval of generics, in conjunction with the BCS as…”
MethodInfluentialShanmugam, S., Baskaran, R., Balakrishnan, P., Thapa, P., Yong, C. S., & Yoo, B. K. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.04.012 · Cited by 144
Yüksel, N., Karataş, A., Özkan, Y., Savaşer, A., Özkan, S. A., & Baykara, T. (2003) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(03)00142-5 · Cited by 144
“[3], piroxicam is a class 2 drug with low solubility and high permeability.”
BackgroundElectrospun Nanofibers in Oral Drug Delivery
Ignatious, F., Sun, L., Lee, C.-P., & Baldoni, J. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0061-6 · Cited by 144
“An in vivo study was conducted using four different formulations: ( 1 ) electrospun Compound I fibers, (2) pellets from electrospun fibers, (3) wet bead milled (D50 1-1.5 micrometer) and (4) non-milled Compound I. Each of the four formulations was dosed at 5 mg/kg in four fasted adult male beagle dogs.”
BackgroundMethodInfluentialVitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Andari Sawaya, R., Jaffe, J., Friedenberg, L., & K. Friedenberg, F. (2012) · Current Drug Metabolism · doi:10.2174/138920012803341339 · Cited by 141
Solid self-emulsifying nitrendipine pellets: Preparation and in vitro/in vivo evaluation
Wang, Z., Sun, J., Wang, Y., Liu, X., Liu, Y., Fu, Q., Meng, P., & He, Z. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.08.014 · Cited by 143
Kumar, R., Thakur, A. K., Chaudhari, P., & Banerjee, N. (2021) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-020-09530-5 · Cited by 154
Mura, P., Maestrelli, F., D’Ambrosio, M., Luceri, C., & Cirri, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040437 · Cited by 156
“However, HCT has been classified as a Class IV drug in the Biopharmaceutical Classification System (BCS) due to its poor solubility and low membrane permeability [5,6], often resulting in a low and variable oral availability [7].”
BackgroundKoyama, E., Sakai, N., Ohori, Y., Kitazawa, K., Izawa, O., Kakegawa, K., Fujino, A., & Ui, M. (2003) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(03)00039-5 · Cited by 143
Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142
Formulation Design of Dry Powders for Inhalation
Weers, J. G., & Miller, D. P. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24574 · Cited by 151
Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine
Hartmanshenn, C., Scherholz, M., & Androulakis, I. P. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9492-y · Cited by 132
“BCS Class I drugs are characterized by high solubility that is independent of pH within the range of 1–8, which includes the physiological pH of the stomach, duodenum, and upper small intestine [169].”
BackgroundTamura, S., Ohike, A., Ibuki, R., Amidon, G. L., & Yamashita, S. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10041 · Cited by 142
Self-citationThe effects of surfactants on the dissolution profiles of poorly water-soluble acidic drugs
Park, S. H., & Choi, H. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.05.004 · Cited by 142
Eldik, L. J. V., Thompson, W. L., Ranaivo, H. R., Behanna, H. A., & Watterson, D. M. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82015-0 · Cited by 149
Nanosuspension Technologies for Delivery of Poorly Soluble Drugs
Yadollahi, R., Vasilev, K. A., & Simović, S. (2015) · Journal of Nanomaterials · doi:10.1155/2015/216375 · Cited by 142
“BCS allocates drugs to one of 4 classes: high solubility, high permeability (class I); low solubility, high permeability (class II); high solubility, low permeability (class III); low solubility, low permeability (class IV) [38].”
BackgroundPaediatric oral biopharmaceutics: Key considerations and current challenges
Batchelor, H. K., Fotaki, N., & Klein, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.10.006 · Cited by 152
Balata, G. F., Eassa, E., Shamrool, H., Zidan, S., & Abourehab, M. A. S. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s95905 · Cited by 141
“This low plasma level may be due to avid metabolism of resveratrol in humans.9 The hydrophobicity of resveratrol is due to the polyphenolic structure, which makes it practically insoluble in water (~3 mg/100 mL) according to the European Pharmacopeia definition, with a log P of 3.1.10 Despite this poor water solubilit…”
BackgroundInfluentialPharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles
Zhou, H. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270002250613 · Cited by 140
“A biopharmaceutical classification system (BCS) for correlating the in vitro drug product dissolution and in vivo bioavailability for immediate-release (IR) solid oral dosage forms was originally proposed by Amidon et al.41 The BCS has established the basis for determining the conditions under which IVIVC correlations…”
MethodSonaje, K., Italia, J. L., Sharma, G., Bhardwaj, V., Tikoo, K., & Kumar, M. N. V. R. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9207-y · Cited by 153
“13 10) can be classified as class IV drug under biopharmaceutical classification system (BCS) (12).”
BackgroundInfluentialEffect of moisture on polyvinylpyrrolidone in accelerated stability testing
Fitzpatrick, S., McCabe, J. F., Petts, C. R., & Booth, S. W. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00375-7 · Cited by 140
Pharmaceutical evaluation of early development candidates “the 100 mg-approach”
Balbach, S., & Korn, C. B. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.01.034 · Cited by 139
TANNERGREN, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.012 · Cited by 138
“The analysis was performed with liquid chromatography–tandem mass spectrometry (LC-MS-MS) in the selected reaction monitoring mode”
MethodDrug–Nutrient Interactions: A Broad View with Implications for Practice
Boullata, J. I., & Hudson, L. M. (2012) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jada.2011.09.002 · Cited by 138
Methods of amorphization and investigation of the amorphous state
Einfalt, T., Planinšek, O., & Hrovat, K. (2013) · Acta Pharmaceutica · doi:10.2478/acph-2013-0026 · Cited by 153
Applications of Polymers as Pharmaceutical Excipients in Solid Oral Dosage Forms
Debotton, N., & Dahan, A. (2016) · Medicinal Research Reviews · doi:10.1002/med.21403 · Cited by 154
Advances in the Use of Tocols as Drug Delivery Vehicles
Constantinides, P. P., Han, J., & Davis, S. S. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-9262-9 · Cited by 151
“TPGS has also been used in oral formulations of R1481 a BCS Class 3 compound (70), having high solubility and low permeability (71), and in the development of microemulsion”
MethodClinical Relevance of Dissolution Testing in Quality by Design
Dickinson, P. A., Lee, W. W., Stott, P. W., Townsend, A. I., Smart, J. P., Ghahramani, P., Hammett, T., Billett, L., Behn, S., Gibb, R. C., et al. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9034-7 · Cited by 138
“For BCS class I drugs in vitro dissolution is already accepted as surrogate for in vivo studies for IR formulations with sufficiently rapid dissolution (8, 10 ) and should thus be possible to apply also within the context of QbD.”
BackgroundMethodInfluentialVariability in bioavailability of small molecular tyrosine kinase inhibitors
Herbrink, M., Nuijen, B., Schellens, J. H. M., & Beijnen, J. H. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.005 · Cited by 149
Miller, J. M., Beig, A., Carr, R. A., Webster, G. K., & Dahan, A. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200460u · Cited by 134
Biopharmaceutics classification system
Chavda, H., Patel, C. N., & Anand, I. (2010) · Systematic Reviews in Pharmacy · doi:10.4103/0975-8453.59514 · Cited by 162
Specialized Solid Form Screening Techniques
Newman, A. W. (2012) · Organic Process Research & Development · doi:10.1021/op300241f · Cited by 137
Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics
Shan, N., Perry, M. L., Weyna, D. R., & Zaworotko, M. J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.942281 · Cited by 136
“Crystal form screening conducted to meet FDA directives [5] has the primary objective of identifying a crystalline solid that is suitable for use in a drug product and is therefore an important step at the preformulation stage of drug development.”
BackgroundJensen, K. T., Löbmann, K., Rades, T., & Grohganz, H. (2014) · Pharmaceutics · doi:10.3390/pharmaceutics6030416 · Cited by 136
“Several approaches have been described for how to overcome the challenges in preparing oral formulations of poorly water-soluble drugs (categorized as Class II and Class IV drugs in the Biopharmaceutics Classification System, BCS) [1].”
BackgroundCarino, S. R., Sperry, D. C., & Hawley, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20495 · Cited by 136
Clinical pharmacokinetics of second generation antisense oligonucleotides
Yu, R. Z., Grundy, J. S., & Geary, R. S. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.737320 · Cited by 135
“Second generation ASOs are Biopharmaceutics Classification System (BCS) class III compounds [26], indicative of high aqueous solubility (under neutral and basic conditions) and low intestinal permeability [due to their size (approximately 7 kDa for 20-mers), hydrophilic nature, and multiple negative charges] [27].”
BackgroundLin, X., Hu, Y., Liu, L., Su, L., Li, N., Yu, J., Tang, B., & Yang, Z. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2408-3 · Cited by 138
Birnbaum, A. K., KARANAM, A. B., Marino, S. E., Barkley, C. M., Remmel, R. P., Roslawski, M. J., Gramling-Aden, M. L., & Leppik, I. E. (2019) · Epilepsia · doi:10.1111/epi.16093 · Cited by 136
Omar, S. M., Ibrahim, F., & Ismail, A. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.01.016 · Cited by 148
“According to Biopharmaceutics Classifi-cation System (BCS), GRI belongs to class II drugs for which the dissolution rate is the primary limiting aspect to the absorption (Amidon et al., 1995).”
Speybroeck, M. V., Mols, R., Mellaerts, R., Thi, T. D., Martens, J. A., Humbeeck, J. V., Annaert, P., den Mooter, G. V., & Augustijns, P. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.04.009 · Cited by 136
Levis, K., Lane, M. E., & Corrigan, O. I. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00645-2 · Cited by 136
Westerhout, J., van de Steeg, E., Grossouw, D., Zeijdner, E. E., Krul, C. A. M., Verwei, M., & Wortelboer, H. M. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.07.003 · Cited by 156
Oral solid gentamicin preparation using emulsifier and adsorbent
Ιtο, Y., Kusawake, T., Ishida, M., Tawa, R., Shibata, N., & Takada, K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.017 · Cited by 135
Liu, D., Xu, H., Tian, B., Yuan, K., Pan, H., Ma, S., Yang, X., & Pan, W.-S. (2012) · AAPS PharmSciTech · doi:10.1208/s12249-011-9750-7 · Cited by 135
Leonard, T. W., Lynch, J., McKenna, M. J., & Brayden, D. J. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.5.685 · Cited by 133
“described the biopharmaceutical classification system for oral delivery of immediate release products [2].”
BackgroundMou, D., Chen, H., Wan, J., Xu, H., & Yang, X. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.04.034 · Cited by 134
Organogels, hydrogels and bigels as transdermal delivery systems for diltiazem hydrochloride
Ibrahim, M. M., Hafez, S. A., & Mahdy, M. A. (2013) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2013.07.006 · Cited by 134
“On the other hand, according to Fick’s first low, the drug efflux increased across the skin as the concentration gradient increased [20].”
BackgroundLipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs
Poovi, G., & Narayanasamy, D. (2018) · Future Journal of Pharmaceutical Sciences · doi:10.1016/j.fjps.2018.04.001 · Cited by 151
Zaborenko, N., Shi, Z., Corredor, C. C., Smith, B. M., Zhang, L., Hermans, A., Neu, C. M., Alam, M. A., Cohen, M. J., Lu, X., et al. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0297-y · Cited by 136
Flavonoids as Human Intestinal α-Glucosidase Inhibitors
Barber, E., Houghton, M. J., & Williamson, G. (2021) · Foods · doi:10.3390/foods10081939 · Cited by 134
“Compared to acarbose and EGCG, lower solubility of tested flavonols was expected due to their structural differences, where compounds with less than 100 μg/mL solubility were considered poorly soluble, as reported previously [28,29].”
Critical freezing rate in freeze drying nanocrystal dispersions
Lee, J., & Cheng, Y. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.12.003 · Cited by 129
Ehrhardt, C., Kneuer, C., Fiegel, J., Hanes, J. S., Schaefer, U. F., Kim, K., & Lehr, C. (2002) · Cell and Tissue Research · doi:10.1007/s00441-002-0548-5 · Cited by 148
“Further transport experiments were performed with cell layers cultured for 1 week by using FITC-labeled dextran (4 kDa, FD4) and two drugs belonging to the biopharmaceutics classification systems (BCS; Amidon et al. 1995 ), viz., the lipophilic propranolol (Pro) and the hydrophilic atenolol (Ate).”
MethodDong, Z., Chatterji, A., Sandhu, H. K., Choi, D. S., Chokshi, H. P., & Shah, N. H. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.12.017 · Cited by 133
Beig, A., Agbaria, R., & Dahan, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068237 · Cited by 143
“ceutical Classification System (BCS), drug candidates with low solubility and favorable permeability characteristics, would be classified as class II compounds [3,4,5,6].”
BackgroundDevelopment of novel ionic liquids based on ampicillin
Ferraz, R., Branco, L. C., Marrucho, I. M., Araújo, J. M. M., Rebelo, L. P. N., da Ponte, M. N., Prudêncio, C., Noronha, J. P., & Petrovski, Ž. (2012) · MedChemComm · doi:10.1039/c2md00269h · Cited by 143
Frenkel, Y. V., Clark, A. D., Das, K., Wang, Y., Lewi, P. J., Janssen, P. A. J., & Arnold, E. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049439i · Cited by 132
Models for drug absorption from the small intestine: where are we and where are we going?
Billat, P.-A., Roger, E., Faure, S., & Lagarce, F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.007 · Cited by 125
Engers, D. A., Teng, J., Jimenez-Novoa, J., Gent, P., Hossack, S., Campbell, C., Thomson, J., Ivanisevic, I., Templeton, A. G. B., Byrn, S. R., et al. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22233 · Cited by 130
Taupitz, T., Dressman, J., Buchanan, C. M., & Klein, S. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.11.003 · Cited by 130
Introduction to computational oral absorption simulation
Sugano, K. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902835506 · Cited by 129
Qi, X., Wang, L., Zhu, J., Hu, Z., & Zhang, J. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.02.047 · Cited by 129
Antibacterial activity of Ionic Liquids based on ampicillin against resistant bacteria
Ferraz, R., Teixeira, V., Rodrigues, D., Fernandes, R., Prudêncio, C., Noronha, J. P., Petrovski, Ž., & Branco, L. C. (2013) · RSC Advances · doi:10.1039/c3ra44286a · Cited by 129
Robertis, S. D., Bonferoni, M. C., Elviri, L., Sandri, G., Caramella, C. M., & Bettini, R. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.966685 · Cited by 140
“These are two key issues clearly underlined by the biopharmaceutical classification 10.1517/17425247.2015.966685 © 2014 Informa UK, Ltd. ISSN 1742-5247, e-ISSN 1744-7593 441 All rights reserved: reproduction in whole or in part not permitted system (BCS) [1] that has become an essential tool for the development of ora…”
BackgroundInfluentialApplication of Density Functional Theory to Molecular Engineering of Pharmaceutical Formulations
Guan, H., Huimin, S., & Zhao, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073262 · Cited by 129
“Significantly, more than 60% of formulation failures in the development of Biophar-maceutics Classification System (BCS) II/IV drugs are attributed to unforeseen molecular interactions between active pharmaceutical ingredients (APIs) and excipients [1].”
InfluentialBiowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ciprofloxacin Hydrochloride
Olivera, M. E., Manzo, R. H., Junginger, H. E., Midha, K. K., Shah, V. P., Stavchansky, S., Dressman, J., & Barends, D. M. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22259 · Cited by 130
“(1) Ciprofloxacine ratiopharm 250 mg/500 mg/750 mg tabletten; (2) Cipro—1 A Pharma(1) 100 mg Filmtabletten (Mono); (3) Cipro—1 A Pharma(1) 250 mg/ 500 mg/750 mg Filmtabletten (Mono); (4) CIPRO BASICS 250 mg/500 mg Filmtabletten (Mono); (5) Ciprobay(1) 250 mg/500 mg/750 mg Filmtabletten (Mono); (6) Ciprobay(1) Uro Film…”
Self-citationThe Science of USP 1 and 2 Dissolution: Present Challenges and Future Relevance
Gray, V. A., Kelly, G., Xia, M., Butler, C., Thomas, S., & Mayock, S. P. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9822-x · Cited by 128
Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles
Thomas, M., Slipper, I. J., Walunj, A., Jain, A., Favretto, M. E., Kallinteri, P., & Douroumis, D. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.12.023 · Cited by 128
Nunes, S., Madureira, A. R., Campos, D. A., Sarmento, B. F. C. C., Gomes, A., Pintado, M., & Reis, F. (2015) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2015.1006768 · Cited by 137
“Indeed, only a small proportion of molecules administered orally are absorbed, because of insufficient gastric residence time, first pass effect, low permeability, and/or low solubility (Amidon et al., 1995).”
BackgroundImproving Solubility and Pharmacokinetics of Meloxicam via Multiple-Component Crystal Formation
Weyna, D. R., Cheney, M. L., Shan, N., Hanna, M., Zaworotko, M. J., Sava, V., Song, S., & Sanchez‐Ramos, J. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300169c · Cited by 128
Dissolution Testing of Semisolid Dosage Forms
(2009) · CRC Press eBooks · doi:10.3109/9781420081275-21 · Cited by 128
Lipid-Based Nanoparticles for Drug-Delivery Systems
Kumar, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814033-8.00008-4 · Cited by 182
Gu, Y., Wang, G., Sun, J., Jia, Y., Wang, W., Xu, M., Lv, T., Zheng, Y., & Sai, Y. (2009) · Food and Chemical Toxicology · doi:10.1016/j.fct.2009.06.013 · Cited by 128
Dahlgren, D., Roos, C., Sjögren, E., & Lennernäs, H. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24258 · Cited by 139
Self-citationTargeting Intestinal Transporters for Optimizing Oral Drug Absorption
Varma, M. V. S., Ambler, C. M., Ullah, M., Rotter, C. J., Sun, H., Litchfield, J., Fenner, K. S., & El‐Kattan, A. F. (2010) · Current Drug Metabolism · doi:10.2174/138920010794328850 · Cited by 138
Thakkar, R., Thakkar, R., Pillai, A. R., Ashour, E. A., & Repka, M. A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118989 · Cited by 128
Hu, J., Johnston, K. P., & Williams, R. O. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(03)00203-3 · Cited by 127
“Carbamazepine (CBZ) is classified by the Biopharmaceutics Classification System (BCS) as a Class II API ( Amidon et al., 1995; Martinez et al., 2002).”
BackgroundOral Delivery of Antisense Oligonucleotides in Man
Tillman, L., Geary, R. S., & Hardee, G. E. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21084 · Cited by 127
Liquisolid technique and its applications in pharmaceutics
Lu, M., Xing, H., Jiang, J., Chen, X., Yang, T., Wang, D., & Ding, P. (2016) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2016.09.007 · Cited by 126
“[5] Amidon GL, Lennernas H, Crison JR, et al.”
BackgroundA review of methods for solubility determination in biopharmaceutical drug characterization
Veseli, A., Žakelj, S., & Kristl, A. (2019) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1665062 · Cited by 126
“[1] and serves as a predictive approach to correlate the in vitro drug dissolution with the in vivo bioavailability.”
BackgroundScientific Considerations of Pharmaceutical Solid Polymorphism in Abbreviated New Drug Applications
Yu, L. X., Furness, M. S., Raw, A., Outlaw, K. P. W., Nashed, N. E., Ramos, E., Miller, S. P. F., Adams, R. C., Fang, F., Patel, R. M., et al. (2003) · Pharmaceutical Research · doi:10.1023/a:1023285627778 · Cited by 126
“The Biopharmaceutics Classification (18,19) criteria of high solubility and rapid dissolution should also be considered in regulatory decisions.”
BackgroundInfluentialLiu, Y., Sun, C., Hao, Y., Jiang, T., Li, Z., & Wang, S. (2010) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3530j · Cited by 126
“It belongs to the BCS class II substance (13-16).”
BackgroundFood for thought: formulating away the food effect – a PEARRL review
O’Shea, J. P., Holm, R., O’Driscoll, C. M., & Griffin, B. T. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12957 · Cited by 134
“The Biopharmaceutical Classification System (BCS) and Biopharmaceutical Drug Disposition Classification system (BDDCS) provide a useful predictor of potential food effects based on drug physicochemical properties, as summarised in Figure 2.([14,15]) The anticipated effects are predicted by the most likely limiting fac…”
Samineni, R., Chimakurthy, J., & Konidala, S. K. (2021) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2021.73554 · Cited by 127
Real, D. A., Bolaños, K., Priotti, J., Yutronic, N., Kogan, M. J., Sierpe, R., & Donoso-González, O. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122131 · Cited by 129
“According to the biopharmaceutical classification system, drugs can be divided into four categories based on their solubility and membrane permeability [18].”
BackgroundUttreja, P., Karnik, I., Youssef, A. A. A., Narala, N., Elkanayati, R. M., Baisa, S., Alshammari, N. D., Banda, S., Vemula, S. K., & Repka, M. A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010063 · Cited by 140
Bioavailability of seocalcitol
Grove, M. F., Müllertz, A., Nielsen, J. L., & Pedersen, G. P. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.02.005 · Cited by 125
Loftsson, Þ., Moya‐Ortega, M. D., Alvarez‐Lorenzo, C., & Concheiro, Á. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12427 · Cited by 142
“According to the BCS, orally administered drugs are divided into four classes based on their solubility and permeability characteristics.([48,49]) In the BCS, a given drug substance is considered ‘highly soluble’ (i.”
BackgroundApplications of Physiologically Based Absorption Models in Drug Discovery and Development
Parrott, N., & Lave, T. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8000155 · Cited by 122
Comparison of fenofibrate–mesoporous silica drug-loading processes for enhanced drug delivery
Ahern, R. J., Hanrahan, J. P., Tobin, J. M., Ryan, K. B., & Crean, A. M. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.026 · Cited by 124
“…2005; Qian and Bogner, 2011), solvent based methods that either involve the suspension of the OMM in a drug–solvent solution (Ambrogi et al., 2012; Andersson et al., 2004; Izquierdo-Barba et al., 2005; Charnay et al., 2004) or impregnation of the OMM by dropwise addition of a concentrated drug…”
MethodPrabhu, S. V., Ortega, M., & Ma, C. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.05.032 · Cited by 124
Prodrug research: futile or fertile?
Testa, B. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.005 · Cited by 157
Cherniakov, I., Izgelov, D., Domb, A. J., & Hoffman, A. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.07.003 · Cited by 131
“…and highly metabolized compounds fall into Class II category of drugs according to both Biopharmaceutical Classification System (BCS) designed by Amidon et al. and Biopharmaceutical Drug Disposition Classification System (BDDCS) outlined by Wu and Benet (Amidon et al., 1995; Wu and Benet, 2005).”
MethodRedenti, E., Szente, L., & Szejtli, J. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1050 · Cited by 123
Zhou, R., Moench, P. A., Heran, C. L., Lu, X., Mathias, N. R., Faria, T. N., Wall, D. A., Hussain, M. A., Smith, R. L., & Sun, D. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-1185-3 · Cited by 123
“pharmacokinetics in man has been previously studied (16,20).”
BackgroundMethodFabrication of drug nanoparticles by evaporative precipitation of nanosuspension
Kakran, M., Sahoo, N. G., Li, L., Judeh, Z. M. A., Wang, Y., Chong, K., & Loh, L. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.09.030 · Cited by 123
Yadav, P. S., Kumar, V., Singh, U. P., Bhat, H. R., & Mazumder, B. (2011) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2011.12.007 · Cited by 122
“Poorly water-soluble drugs are associated with slow drug absorption leading eventually to inadequate and variable bio-availability (Amidon et al., 1995; Leuner and Dressman, 2000).”
Metadata
- Authors
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R.
- Affiliations
- University of Michigan (US)
- Uppsala University (SE)
- United States Food and Drug Administration (US)
- Therapeutics Systems Research Laboratories (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 1995-03
- Volume
- 12
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1498305210
- Cited by
- 5,430
- References
- 29
- Citations by year
- 2026: 170 · 2025: 201 · 2024: 182 · 2023: 240 · 2022: 266 · 2021: 282 · 2020: 299 · 2019: 241 · 2018: 278 · 2017: 267 · 2016: 283 · 2015: 283 · 2014: 302 · 2013: 296 · 2012: 302
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- U.S. Food and Drug Administration (FD-01462)
- National Institute of General Medical Sciences (GM 37188, R01GM037188)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- in vitro-in vivo correlation, drug dissolution, bioavailability, gastrointestinal permeability, oral drug absorption, solubility, transport modeling, dissolution profile, surfactants
- MeSH terms
- Biological Availability, Cimetidine, Pharmaceutical Preparations, Gastric Emptying, Jejunum, Mathematics, Models, Theoretical, Permeability, Piroxicam, Solubility, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.